Celcuity INC 10-Q quarterly reports

Celcuity Inc. announced FDA approval for its REVTORPYK (gedatolisib) therapy for HR+/HER2- advanced breast cancer, alongside robust clinical trial results and significant capital raises.

Celcuity Inc. reported a widened net loss in Q1 2026 due to increased R&D and commercialization expenses, while advancing its lead drug candidate gedatolisib with positive clinical trial results and an FDA Priority Review.

Celcuity Inc. announced positive Phase 3 clinical trial results for gedatolisib in HR+/HER2advanced breast cancer and significantly bolstered its liquidity with over $286 million in new financing.

Celcuity Inc. announced positive topline Phase 3 VIKTORIA-1 data for gedatolisib in breast cancer and secured over $286 million in new capital to extend its operational runway through 2027.

Celcuity Inc. announces its Q1 2025 financial results and provides updates on its ongoing clinical trials, including the expected timing of topline data for VIKTORIA-1 and CELC-G-201.

Celcuity Inc. announced its third quarter 2024 financial results, highlighting increased research and development spending and progress in its clinical trials for gedatolisib.

Celcuity Inc. reported a net loss for the second quarter of 2024, while also advancing its clinical programs and securing significant funding.

Celcuity Inc. amended its warrants to allow for cashless exercises and reported a net loss of $21.6 million for the first quarter of 2024, driven by increased research and development expenses.